| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
SYK
Stryker
|
Oct 30, 2026 | HOLD |
Strong Buy
+18.5% avg upside
38 analysts
|
$300.00
2.85% Upside
|
+6.5% | Β· |
|
ESTA
Establishment Labs Holdings
|
Oct 29, 2026 | BUY |
Strong Buy
+45.5% avg upside
13 analysts
|
$105.00
68.08% Upside
|
+1.6% | Β· |
|
AXGN
AxoGen
|
Oct 29, 2026 | BUY |
Strong Buy
-17.4% avg upside
21 analysts
|
$60.00
21.50% Upside
|
+11.6% | Β· |
|
KIDS
OrthoPediatrics
|
Oct 28, 2026 | BUY |
Strong Buy
+9.5% avg upside
10 analysts
|
$30.00
2.76% Downside
|
+2.0% | Β· |
|
INMD
InMode
|
Oct 14, 2026 | HOLD |
Buy
+46.1% avg upside
9 analysts
|
$15.00
13.44% Upside
|
-9.5% | Β· |
|
SIBN
SI-Bone
|
Oct 14, 2026 | BUY |
Strong Buy
+22.7% avg upside
18 analysts
|
$27.00
27.11% Upside
|
+18.9% | Β· |
|
SNN
Smith & Nephew Snats
|
Sep 23, 2026 | HOLD |
Buy
+9.7% avg upside
15 analysts
|
$30.00
1.03% Upside
|
+15.1% | Β· |
|
ENOV
Enovis
|
Sep 01, 2026 | BUY |
Strong Buy
+226.7% avg upside
39 analysts
|
$45.00
125.98% Upside
|
+32.6% | Β· |
|
TELA
TELA Bio
|
Aug 31, 2026 | BUY |
Strong Buy
+824.3% avg upside
9 analysts
|
$2.00
146.92% Upside
|
+6.8% | Β· |
|
OFIX
Orthofix Medical
|
Aug 31, 2026 | BUY |
Buy
+203.8% avg upside
15 analysts
|
$13.00
43.26% Upside
|
-29.0% | Β· |
|
GMED
Globus Medical
|
Aug 28, 2026 | BUY |
Strong Buy
+18.9% avg upside
24 analysts
|
$115.00
47.36% Upside
|
-14.3% | Β· |
|
BVS
Bioventus
|
Aug 17, 2026 | BUY |
Strong Buy
+5.1% avg upside
8 analysts
|
$19.00
42.59% Upside
|
-23.6% | Β· |
|
KRMD
REPRO-MED Systems
|
Aug 12, 2026 | BUY |
Strong Buy
+113.6% avg upside
9 analysts
|
$6.00
100.59% Upside
|
+4.7% | Β· |
|
ZBH
Zimmer Biomet Holdings
|
Aug 10, 2026 | BUY |
Buy
+20.5% avg upside
39 analysts
|
$100.00
5.86% Upside
|
+5.8% | Β· |
|
VCEL
Vericel
|
Jun 24, 2026 | BUY |
Strong Buy
+16.2% avg upside
16 analysts
|
$58.00
43.98% Upside
|
+37.9% | Β· |
|
ATEC
Alphatec Holdings
|
May 06, 2026 | BUY |
Strong Buy
+117.0% avg upside
23 analysts
|
$23.00
226.77% Upside
|
-0.7% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.